Connect with us

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website. .

Top Stories

England to offer COVID vaccine to all 12- to 15-year-olds

2021 09 13T154029Z 1 LYNXMPEH8C0OS RTROPTP 4 HEALTH CORONAVIRUS BRITAIN CHILDREN - Global Banking | Finance

By Alistair Smout

LONDON (Reuters) -All 12- to 15-year-olds in England will be offered a COVID-19 vaccine after top medical advisers said on Monday that children would benefit from reduced disruption to their education.

The British government confirmed that the offer would be extended to all children aged 12-15 after a unanimous recommendation by the Chief Medical Officers (CMOs) from the four nations of the United Kingdom.

“I have accepted the recommendation from the Chief Medical Officers to expand vaccination to those aged 12 to 15 – protecting young people from catching COVID-19, reducing transmission in schools and keeping pupils in the classroom,” health minister Sajid Javid said in a statement.

Rollout to the cohort in England will begin next week. Scotland, Wales and Northern Ireland set their own health policy, though each devolved administration received the same advice from their respective CMO.

The CMOs recommended that children aged 12-15 in Britain get a first shot of the Pfizer-BioNTech vaccine, after the Joint Committee on Vaccination and Immunisation (JCVI) earlier this month decided against making the recommendation.

The children will be offered Pfizer-BioNTech’s vaccine. Vulnerable children in the age bracket were already eligible for the shots.

The United States, Israel and some European countries have rolled out vaccinations to children more broadly, putting pressure on the British government to follow suit.

There have been more than 134,000 deaths from COVID-19 in Britain https://graphics.reuters.com/world-coronavirus-tracker-and-maps/countries-and-territories/united-kingdom, and a rapid start to its vaccination rollout has slowed, with 81% of those over 16 receiving two vaccine doses.

The JCVI had previously said the decision to vaccinate children was “finely balanced” as the government then sought further advice on the issue.

The CMOs in a letter said that vaccinating children could reduce COVID-19 transmission and thus disruption to schools, and those benefits “on balance provide sufficient extra advantage… to recommend in favour of vaccinating this group.”

“(Vaccination) will reduce education disruption,” Chris Whitty, England’s chief medical officer, said at a news briefing.

“We do not think that this is a panacea, there’s no silver bullet … but we think it is an important and potentially useful additional tool to help reduce the public health impacts that come through educational disruption.”

The CMOs said second doses would not be offered to the age group until at least spring as they would wait for more data from around the world.

(Reporting by Alistair Smout and Michael Holden; editing by Jonathan Oatis and Grant McCool)

Global Banking & Finance Review

 

Why waste money on news and opinions when you can access them for free?

Take advantage of our newsletter subscription and stay informed on the go!


By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review │ Banking │ Finance │ Technology. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Post